首页 | 本学科首页   官方微博 | 高级检索  
     

ALK+弥漫大B细胞淋巴瘤的研究进展
引用本文:付骞千,张甜甜(综述),翟琼莉(审校). ALK+弥漫大B细胞淋巴瘤的研究进展[J]. 中国肿瘤临床, 2013, 0(14): 873-876. DOI: 10.3969/j.issn.1000-8179.2013.14.016
作者姓名:付骞千  张甜甜(综述)  翟琼莉(审校)
作者单位:天津医科大学附属肿瘤医院病理科, 天津市肿瘤防治重点实验室(天津市300060)
基金项目:本文课题受国家自然科学基金(项目编号:编号81272361)
摘    要:ALK+弥漫大B细胞淋巴瘤(anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma, ALK+DLBCL)是弥漫大B细胞淋巴瘤的一种罕见的亚型, 具有特殊的免疫母细胞或浆母细胞样的形态学特点, 免疫表型独具特征, 细胞遗传学异常, 在儿童和成人都可发生。此病虽然罕见, 但是其临床过程具有侵袭性且预后不良, 因此明确认识该疾病的特点是诊断的关键。ALK+DLBCL对传统化疗方案反应性差, 最近推出的小分子ALK抑制剂可能对这种疾病的患者提供了一个潜在的新的治疗选择。 

关 键 词:间变性淋巴瘤激酶   弥漫大B细胞淋巴瘤   免疫组织化学
收稿时间:2013-03-11

Research progress of ALK+diffuse large B-cell lymphoma
Qianqian FU , Tiantian ZHANG , Qiongli ZHAI. Research progress of ALK+diffuse large B-cell lymphoma[J]. Chinese Journal of Clinical Oncology, 2013, 0(14): 873-876. DOI: 10.3969/j.issn.1000-8179.2013.14.016
Authors:Qianqian FU    Tiantian ZHANG    Qiongli ZHAI
Affiliation:Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, Key Laboratory of Cancer Prevention and Treatment of Tianjin City, Tianjin 300060, China
Abstract:Anaplastic lymphoma kinase-positive(ALK+) diffuse large B-cell lymphoma(DLBCL) is a rare subtype of DLBCL.ALK+DLBCL has a characteristic immunoblastic/plasmablastic morphology, a distinct immunophenotypic profile, and recurrent cytogenetic/molecular genetic abnormalities.The occurrence of this type of lymphoma has been reported in both adult and pediatric populations.Although rare, this new entity should be recognized because most cases follow an aggressive clinical course with a poor prognosis.The response of ALK+DLBCL to conventional chemotherapy is poor.The recently discovered small molecule ALK inhibitor may provide a potential therapeutic option for patients with this disease. 
Keywords:anaplastic lymphoma kinase  diffuse large B-cell lymphoma  immunohistochemistry
本文献已被 万方数据 等数据库收录!
点击此处可从《中国肿瘤临床》浏览原始摘要信息
点击此处可从《中国肿瘤临床》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号